Login to Your Account



Shelf awareness: Adicet’s immune effort draws eye of Regeneron; $25M paid

By Randy Osborne
Staff Writer

Tuesday, August 2, 2016

In the midst of what CEO Aya Jakobovits told BioWorld Today is “growth spree,” Adicet Bio Inc. bagged a $25 million up-front, five-year deal with Regeneron Pharmaceuticals Inc. to come up with off-the-shelf immune cell therapies that could attack solid tumors as well as blood cancers.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription